NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
it's the first oral systemic full-spectrum botanical drug moving through the FDA,” says Stanley. Stanley explained that Phase I trials were completed in Australia, finding positive results about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback